Worldwide provided flexible, full‑service support to an emerging biotech developing the first bladder cancer therapy breakthrough in decades, while simultaneously navigating shifting priorities, system gaps, and pandemic‑era challenges. By leading cross‑CRO coordination, accelerating site activation, and ensuring seamless operational continuity, Worldwide enabled the sponsor to achieve Fast Track designation and a successful IPO.
Tailored Approach Supports Bladder Cancer Breakthrough
Read more